Nevanimibe hydrochloride is under clinical development by Tempest Therapeutics and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Nevanimibe hydrochloride’s likelihood of approval (LoA) and phase transition for Adrenocortical Carcinoma (Adrenal Cortex Cancer) took place on 14 Apr 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Nevanimibe hydrochloride Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Nevanimibe hydrochloride overview

Nevanimibe hydrochloride (ATOR-1) is under development for the treatment of adrenocortical carcinoma, congenital adrenal hyperplasia. The drug candidate is administered orally as tablets or capsules. It acts by targeting acetyl CoA acetyltransferase mitochondrial (ACAT-1).

It was also under development for endogenous Cushing's syndrome.

Tempest Therapeutics overview

Tempest Therapeutics (Tempest) formerly Millendo Therapeutics, Inc. is a biotechnology company. It develops small molecule medicines that regulate anti-tumor immunity pathways. The company’s pipeline portfolio includes TPST-1495, an IDO (enzyme) inhibitor that generates kynurenine, a powerful immunosuppressive factor, which regulates immune cells in the tumor microenvironment (TME) and blocks anti-tumor immunity; TPST-1120, an antagonist that acts against peroxisome proliferator-activated receptor alpha (PPARa); and E-prostanoid (EP) receptor antagonists whose prostaglandin E2 (PGE2) pathway facilitates immune suppression in the TME. Tempest is also developing an orally available inhibitor of TREX-1 designed to activate cGAS/STING pathway, for the development of anti-tumor immunity. TempestTx is headquartered in South San Francisco, California, the US.

Quick View Nevanimibe hydrochloride LOA Data

Report Segments
  • Innovator
Drug Name
  • Nevanimibe hydrochloride
Administration Pathway
  • Oral
Therapeutic Areas
  • Hormonal Disorders
  • Metabolic Disorders
  • Oncology
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.